Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of “Buy” by Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have received an average recommendation of “Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.38.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday, January 14th.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC purchased a new position in shares of Corvus Pharmaceuticals in the 4th quarter worth about $47,000. Nwam LLC bought a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at about $53,000. PKS Advisory Services LLC purchased a new position in Corvus Pharmaceuticals in the fourth quarter worth about $56,000. Alpine Global Management LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $62,000. Finally, ExodusPoint Capital Management LP bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $72,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

Shares of CRVS stock opened at $4.25 on Tuesday. The stock has a market capitalization of $273.09 million, a price-to-earnings ratio of -4.57 and a beta of 0.91. The company’s fifty day simple moving average is $4.72 and its two-hundred day simple moving average is $6.10. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.